Fig. 2: CXCL12 and SCF improve FLT3L-driven DC differentiation.

a Representative FACS plots and absolute number of CD141⁺Clec9A⁺, CD1c⁺CD206⁻, and CD1c⁺CD206⁺ cells generated from CD34⁺ HSPCs cultured with MS5 expressing human FLT3L (MS5_F) in combination with human SCF (S), TPO (T), and CXCL12 (12). Day 15 flow cytometry analysis of n = 3 cord blood donors in three independent experiments. *p < 0.05, one-way ANOVA test with Tukey’s multiple comparisons. b ELISA detecting human GM-CSF in the supernatant of CD34⁺ HSPCs cultured with engineered MS5 expressing human FLT3L, SCF and CXCL12 (MS5_FS12) at day 15 for n = 2 (MS5_CTRL ± CD34⁺ HSPC and MS5_FS12 only) and n = 4 (MS5_FS12 + CD34⁺ HSPC) independent donors. c Absolute number of human DC subsets generated in vitro from CD34⁺ HSPC using MS5_FS12 stromal cells in the presence of human GM-CSF neutralizing antibody as compared to isotype control (n = 6 independent donors in two experiments). Data are presented as floating bars ranging from min to max and line represents median a, c or as bar graphs with mean ± SEM (b).